Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03327792 · ClinicalTrials.gov registry record · Phase 1
Mavoglurant in Alcohol Drinking
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT03327792 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 34 participants.
The verdict
NCT03327792, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this alcohol-interaction pilot study is to provide information on the effect of mavoglurant on the pharmacokinetics of alcohol and on alcohol responses, including stimulation, sedation, intoxication, body sway and physiological responses. The investigators propose to test the effects of 200 mg mavoglurant versus placebo on alcohol related responses. This is a between subjects double blind randomized design in which the investigators plan to run 40 subjects to obtain 28 completers.
Interventions
- DRUG Placebo
- DRUG Mavoglurant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2018-02-07 |
| Est. Completion | 2023-07-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03327792
The ClinicalTrials.gov registry entry for NCT03327792 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03327792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03327792 about?
NCT03327792 is a clinical study titled "Mavoglurant in Alcohol Drinking". The purpose of this alcohol-interaction pilot study is to provide information on the effect of mavoglurant on the pharmacokinetics of alcohol and on alcohol responses, including stimulation, sedation, intoxication, body sway and physiological responses. The investigators propose to test the effects ...
What is the current status of trial NCT03327792?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2018-02-07. Estimated completion is 2023-07-13.
What interventions are being tested in trial NCT03327792?
The interventions under investigation include: Placebo (DRUG), Mavoglurant (DRUG).
Who is sponsoring clinical trial NCT03327792?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.